$9.0 million for the quarter ended December 31, 2010 compared to the same quarter in 2009 reflected primarily: (1) an increase in expenses incurred in connection with our FREEDOM-M and FREEDOM-C2 Phase III clinical trials, which was largely offset by a decrease in expenses related to our inhaled treprostinil program; and (2) an increase of $9.3 million in expenses related to our development of beraprost-MR, which includes $9.0 million in milestone-related expenses.
Share-based compensation. The increase in share-based compensation expense of $8.6 million for the quarter ended December 31, 2010 over the same quarter in 2009 reflected: (1) an increase in the fair value of awards granted under our Share Tracking Awards Plan (STAP), principally as a result of the increase in the price of our common stock; (2) an increase in the number of outstanding STAP awards; and (3) increases in both the number of STAP awards vested and the time that unvested STAP awards had accrued toward vesting as of December 31, 2010.
Other. Other research and development expenses increased $3.6 million during the quarter ended December 31, 2010 compared to the same quarter in 2009 reflected primarily an increase in personnel, depreciation and overhead costs supporting our research mainly because 2010 was the first full year of operations of our new facilities in North Carolina and Maryland. Research and development expenses for our individual disease platforms include only direct labor and related direct costs.
The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009CategoryGeneral and administrative
68,606Sales and marketing
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States2
. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States3
. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States4
. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 20085
. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees6
. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States7
. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing8
. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 20099
. United Therapeutics Reports Third Quarter 2008 Financial Results10
. Lilly Contributes $11.1 Million to United Way Annual Campaign11
. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System